Press Releases Keyword Search News Category Financial Year None201920182017201620152014 Date Title 05/15/19 MediciNova to Present at the 20th Annual B. Riley FBR Institutional Investor Conference 05/07/19 MediciNova Participated in the RECEDE Phase 3 Degenerative Cervical Myelopathy Trial Kick-off Meeting, DCM Symposium and the Official Launch of Myelopathy.org in London, United Kingdom 04/23/19 MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma 04/15/19 MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS 04/03/19 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in China 04/01/19 MediciNova Announces Results of Subgroup Analysis from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS 03/24/19 MediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive Multiple Sclerosis at the 71st American Academy of Neurology Annual Meeting in Philadelphia, Pennsylvania 03/05/19 MediciNova Announces MN-001 Research Collaboration with The Jikei University School of Medicine in Tokyo, Japan 02/28/19 MediciNova Announces the Publication of Results of the Animal Model Study of MN‑166 (ibudilast) in Glioblastoma in Scientific Reports 01/21/19 MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other Neurodegenerative Diseases 01/08/19 MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma 01/07/19 MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Japan
